Filtered By:
Source: Cancer and Metabolism
Drug: Tarceva
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
ConclusionsSimilar to the genomic heterogeneity observed in TNBC, our results reveal metabolic heterogeneity among TNBC subtypes and demonstrate that understanding metabolic profiles and drug responses may prove valuable in targeting TNBC subtypes and identifying therapeutic susceptibilities in TNBC patients. Perturbation of metabolic pathways sensitizes TNBC to inhibition of receptor tyrosine kinases. Such metabolic vulnerabilities offer promise for effective therapeutic targeting for TNBC patients.
Source: Cancer and Metabolism - August 22, 2017 Category: Cancer & Oncology Source Type: research
